1
|
Evans RW. The Postconcussion Syndrome and Posttraumatic Headaches in Civilians, Soldiers, and Athletes. Neurol Clin 2024; 42:341-373. [PMID: 38575256 DOI: 10.1016/j.ncl.2023.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/06/2024]
Abstract
Posttraumatic headaches are one of the most common and controversial secondary headache types. After a mild traumatic brain, an estimated 11% to 82% of people develop a postconcussion syndrome, which has been controversial for more than 160 years. Headache is estimated as present in 30% to 90% of patients after a mild head injury. Most headaches are tension-type-like or migraine-like. Headaches in civilians, soldiers, athletes, and postcraniotomy are reviewed. The treatments are the same as for the primary headaches. Persistent posttraumatic headaches can continue for many years.
Collapse
Affiliation(s)
- Randolph W Evans
- Neurology, Baylor College of Medicine, 1200 Binz #1370, Houston, TX 77004, USA.
| |
Collapse
|
2
|
MacKenzie HM, Robinson M, McIntyre A. Tolerability of pharmacological agents in the treatment of headache following brain injury: a scoping review. Brain Inj 2023; 37:1-10. [PMID: 36637191 DOI: 10.1080/02699052.2023.2165156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2021] [Revised: 09/12/2022] [Accepted: 01/02/2023] [Indexed: 01/14/2023]
Abstract
BACKGROUND While systematic reviews have examined medication effectiveness for post-traumatic headache (PTH), they have not assessed tolerability. OBJECTIVE To conduct a scoping review to characterize the adverse effects of pharmacotherapy for PTH. METHODS CINAHL, CMA Infobase, Cochrane Library, Embase, Epistemonikos, MEDLINE, PEDro, PsycInfo, Scopus, SportDiscus, TRIP and the University of York Center for Reviews and Dissemination were searched. Studies meeting these criteria were included 1) English language, 2) involved humans with traumatic brain injury (TBI), 3) a medication for PTH was administered and 4) reported tolerability outcomes. Author(s), publication year, country of origin, study design, sample demographics, medication type, comparator, dose, treatment duration, adverse effect type and rate, discontinuation rate, and effectiveness outcomes were extracted. RESULTS The search yielded 2941 records; 11 studies were included (n = 324 subjects). All subjects had mild TBI except for one with moderate TBI. The following therapies were examined 1) abortive (dihydroergotamine N = 1; metoclopramide N = 1; indomethacin N = 3), 2) prophylactic (divalproex sodium N = 1; amantadine N = 1; erenumab N = 2; amitriptyline N = 2). No serious adverse effects occurred. Observed adverse effects overlap with common symptoms of TBI. CONCLUSION The unique needs of people with TBI must be considered when instituting pharmacotherapy. More studies specifically evaluating medication tolerability in PTH are needed.
Collapse
Affiliation(s)
- Heather M MacKenzie
- Parkwood Institute, St. Joseph's Health Care London, London, Canada
- Department of Physical Medicine and Rehabilitation, Schulich School of Medicine and Dentistry, Western University, London, Canada
| | | | - Amanda McIntyre
- Parkwood Institute Research, Parkwood Institute, London, Canada
| |
Collapse
|
3
|
Labastida-Ramírez A, Benemei S, Albanese M, D’Amico A, Grillo G, Grosu O, Ertem DH, Mecklenburg J, Fedorova EP, Řehulka P, di Cola FS, Lopez JT, Vashchenko N, MaassenVanDenBrink A, Martelletti P. Persistent post-traumatic headache: a migrainous loop or not? The clinical evidence. J Headache Pain 2020; 21:55. [PMID: 32448142 PMCID: PMC7245945 DOI: 10.1186/s10194-020-01122-5] [Citation(s) in RCA: 31] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2020] [Accepted: 05/05/2020] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Headache is a common complication of traumatic brain injury. The International Headache Society defines post-traumatic headache as a secondary headache attributed to trauma or injury to the head that develops within seven days following trauma. Acute post-traumatic headache resolves after 3 months, but persistent post-traumatic headache usually lasts much longer and accounts for 4% of all secondary headache disorders. MAIN BODY The clinical features of post-traumatic headache after traumatic brain injury resemble various types of primary headaches and the most frequent are migraine-like or tension-type-like phenotypes. The neuroimaging studies that have compared persistent post-traumatic headache and migraine found different structural and functional brain changes, although migraine and post-traumatic headache may be clinically similar. Therapy of various clinical phenotypes of post-traumatic headache almost entirely mirrors the therapy of the corresponding primary headache and are currently based on expert opinion rather than scientific evidence. Pharmacologic therapies include both abortive and prophylactic agents with prophylaxis targeting comorbidities, especially impaired sleep and post-traumatic disorder. There are also effective options for non-pharmacologic therapy of post-traumatic headache, including cognitive-behavioral approaches, onabotulinum toxin injections, life-style considerations, etc. CONCLUSION: Notwithstanding some phenotypic similarities, persistent post-traumatic headache after traumatic brain injury, is considered a separate phenomenon from migraine but available data is inconclusive. High-quality studies are further required to investigate the pathophysiological mechanisms of this secondary headache, in order to identify new targets for treatment and to prevent disability.
Collapse
Affiliation(s)
- Alejandro Labastida-Ramírez
- Division of Vascular Medicine and Pharmacology, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - Silvia Benemei
- Health Sciences Department, University of Florence, and Headache Centre, Careggi University Hospital, Florence, Italy
| | - Maria Albanese
- Department of Systems Medicine, Neurology Unit, University of Rome “Tor Vergata”, “Tor Vergata” Hospital, Rome, Italy
| | - Antonina D’Amico
- Department of Child Neuropsychiatry, University of Palermo, Palermo, Italy
| | - Giovanni Grillo
- Department of Child Neuropsychiatry, A.R.N.A.S. Civico, P.O. Giovanni di Cristina Ospedale dei Bambini, Palermo, Italy
| | - Oxana Grosu
- Diomid Gherman Institute of Neurology and Neurosurgery, Headache Centre and Nicolae Testemițanu State University of Medicine and Pharmacy, Chișinău, Republic of Moldova
| | - Devrimsel Harika Ertem
- Department of Neurology, University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey
| | - Jasper Mecklenburg
- Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany
| | | | - Pavel Řehulka
- Department of Neurology, St. Anne’s University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic
| | - Francesca Schiano di Cola
- Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| | - Javier Trigo Lopez
- Department of Neurology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
| | - Nina Vashchenko
- University Clinic of Nervous Diseases, Sechenov First Moscow State Medical University, Moscow, Russian Federation
| | | | - Paolo Martelletti
- Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy
| | - On behalf of the European Headache Federation School of Advanced Studies (EHF-SAS)
- Division of Vascular Medicine and Pharmacology, Erasmus University Medical Center, Rotterdam, The Netherlands
- Health Sciences Department, University of Florence, and Headache Centre, Careggi University Hospital, Florence, Italy
- Department of Systems Medicine, Neurology Unit, University of Rome “Tor Vergata”, “Tor Vergata” Hospital, Rome, Italy
- Department of Child Neuropsychiatry, University of Palermo, Palermo, Italy
- Department of Child Neuropsychiatry, A.R.N.A.S. Civico, P.O. Giovanni di Cristina Ospedale dei Bambini, Palermo, Italy
- Diomid Gherman Institute of Neurology and Neurosurgery, Headache Centre and Nicolae Testemițanu State University of Medicine and Pharmacy, Chișinău, Republic of Moldova
- Department of Neurology, University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey
- Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany
- Department of Neurology, Zdorovie Clinic, Tomsk, Russia
- Department of Neurology, St. Anne’s University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic
- Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
- Department of Neurology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
- University Clinic of Nervous Diseases, Sechenov First Moscow State Medical University, Moscow, Russian Federation
- Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy
| |
Collapse
|